Search

Displaying results 2441 - 2450 of 9132 in total
  1. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. … These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs.

  2. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use. … Human umbilical cord is a rich source of hematopoietic stem cells and progenitor cells that are capable of proliferation _in vitro_.

  3. Drug

    INGN 225

    go.drugbank.com/drugs/DB05325
    Investigational

    INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.

  4. Drug

    Rifampin

    go.drugbank.com/drugs/DB01045
    ApprovedInvestigational

    Rifampin, also known as rifampicin, is a broad-spectrum antimicrobial [A263748] that was first discovered in 1965 [A263753] and clinically used in 1968.

  5. Drug

    Quisqualic acid

    go.drugbank.com/drugs/DB02999
    Experimental

    Quisqualic acid is an agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium

  6. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. … Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling

  7. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

    Synonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  8. Drug

    Norgestrel

    go.drugbank.com/drugs/DB09389
    Approved

    Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.

  9. Drug

    Melphalan

    go.drugbank.com/drugs/DB01042
    ApprovedInvestigational

    Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent.

    Synonyms: L-PAM
  10. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA. … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).